Multicenter, Randomized, Blinded, Placebo Controlled, Cross Over, Single Dose Study to Assess the Effect of Indacaterol (150 μg) Versus Tiotropium (18 μg) on Inspiratory Capacity in Moderate COPD Patients.

Trial Profile

Multicenter, Randomized, Blinded, Placebo Controlled, Cross Over, Single Dose Study to Assess the Effect of Indacaterol (150 μg) Versus Tiotropium (18 μg) on Inspiratory Capacity in Moderate COPD Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 May 2016

At a glance

  • Drugs Indacaterol; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Oct 2011 Primary endpoint 'Inspiratory-capacity' has been met (3065195).
    • 27 Oct 2011 Results published in the Respiratory Medicine.
    • 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top